← Back to directory
EC
Epidarex Capital
Bethesda, Maryland, USA; Edinburgh, UKWebsite ↗
Epidarex Capital is a transatlantic venture capital firm that invests in early-stage, high-growth life science and health technology companies in emerging research hubs across the UK and US. The firm focuses on building breakthrough companies that translate novel science into successful drugs and medical devices.
Last raised
Jan 2026
6 mo ago
Latest fund size
$145M
Epidarex Capital IV, LP
AUM
$395M
estimated
Funds raised
Capital this firm has raised, newest first
Epidarex Capital IV, LP
Jan 2026
$145M
Epidarex Capital III UK LP
Jun 2020
$126.3M
Epidarex Capital I
May 2014
—
Epidarex Capital II
Jan 2013
—
Recent investments
Companies this firm has funded, newest first
| Company | Round | Amount | Date | Source |
|---|---|---|---|---|
| Leucid Bio | Series A | — | Feb 2025 | |
| Theolytics | Series B | $24.5M | Apr 2024 | |
| Curve Therapeutics | Series A | — | Feb 2024 | |
| Epsilogen | Series B | $41.2M | Mar 2022 | |
| Topas Therapeutics | Series B | $26M | Oct 2020 | |
| Libra TherapeuticsLead | Series A | $29M | Sep 2020 | |
| Lunac TherapeuticsLead | Series A | — | Jun 2020 | |
| NodThera | Series B | $55M | Jun 2020 |
Sources
Where this data came from